[Asia Economy Reporter Ji Yeon-jin] Celltrion announced on the 24th that it has signed a supply contract worth 160 billion KRW for biosimilar antibody drugs (Remsima IV, Herzuma, CT-P16) with Celltrion Healthcare. The contract period is from today until the 30th of next month.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
